{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:34:58Z","timestamp":1789180498836,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1249,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1124\/jpet.121.000688","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T15:40:28Z","timestamp":1620661228000},"page":"166-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development"],"prefix":"10.1016","volume":"378","author":[{"given":"Wei","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeenat","family":"Shyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald C","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.121.000688_bib1","doi-asserted-by":"crossref","unstructured":"Alexander SPH, Ball JK and Tsoleridis T (2020) Coronavirus (CoV) proteins (version 2020.5) in the IUPHAR\/BPS Guide to Pharmacology Database. IUPHAR\/BPS Guide to Pharmacology CITE. 2020.","DOI":"10.2218\/gtopdb\/F118\/2020.5"},{"key":"10.1124\/jpet.121.000688_bib2","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"10.1124\/jpet.121.000688_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds","volume":"115","author":"B\u00e1ez-Santos","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1124\/jpet.121.000688_bib4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrmicro3046","article-title":"The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection","volume":"11","author":"Bartenschlager","year":"2013","journal-title":"Nat Rev Microbiol"},{"key":"10.1124\/jpet.121.000688_bib5","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1056\/NEJMcp2009575","article-title":"Severe Covid-19","volume":"383","author":"Berlin","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.121.000688_bib6","doi-asserted-by":"crossref","unstructured":"Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E and Eng H et al (2020) Discovery of a novel inhibitor of coronavirus 3CL protease as a clinical candidate for the potential treatment of COVID-19. bioRxiv. 2020.2009.2012.293498","DOI":"10.1101\/2020.09.12.293498"},{"key":"10.1124\/jpet.121.000688_bib7","doi-asserted-by":"crossref","first-page":"10423","DOI":"10.1002\/anie.202016961","article-title":"Targeting the main protease of SARS-CoV-2: from the establishment of high throughput screening to the design of tailored inhibitors","volume":"60","author":"Breidenbach","year":"2021","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1124\/jpet.121.000688_bib8","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.121.000688_bib9","first-page":"399","article-title":"Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: a multicentre retrospective matched cohort study","volume":"9","author":"Chan","year":"2003","journal-title":"Hong Kong Med J"},{"key":"10.1124\/jpet.121.000688_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s13238-010-0011-4","article-title":"Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode","volume":"1","author":"Chen","year":"2010","journal-title":"Protein Cell"},{"key":"10.1124\/jpet.121.000688_bib11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results","volume":"384","author":"Pan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.121.000688_bib12","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1124\/jpet.121.000688_bib13","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.bcp.2013.09.010","article-title":"Dancing with chemical formulae of antivirals: A panoramic view (Part 2)","volume":"86","author":"De Clercq","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.121.000688_bib14","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"10.1124\/jpet.121.000688_bib15","unstructured":"de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O\u2019Connor R, Steppan C, Anderson AS, Binder J and Dittmann M (2020) Comparative study of a 3CLpro inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models. bioRxiv 2020.2008.2028.272880"},{"key":"10.1124\/jpet.121.000688_bib16","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1021\/acschembio.5b00753","article-title":"NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells","volume":"11","author":"Dixon","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1124\/jpet.121.000688_bib17","doi-asserted-by":"crossref","first-page":"e01265-20","DOI":"10.1128\/JVI.01265-20","article-title":"Development of a fluorescence-based, high-throughput SARS-CoV-2 3CLpro reporter assay","volume":"94","author":"Froggatt","year":"2020","journal-title":"J Virol"},{"key":"10.1124\/jpet.121.000688_bib18","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","article-title":"Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV\/AIDS","volume":"59","author":"Ghosh","year":"2016","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.121.000688_bib19","doi-asserted-by":"crossref","first-page":"114225","DOI":"10.1016\/j.bcp.2020.114225","article-title":"Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches","volume":"182","author":"Gioia","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.121.000688_bib20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"10.1124\/jpet.121.000688_bib21","doi-asserted-by":"crossref","first-page":"13600","DOI":"10.1128\/JVI.78.24.13600-13612.2004","article-title":"Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity","volume":"78","author":"Harcourt","year":"2004","journal-title":"J Virol"},{"key":"10.1124\/jpet.121.000688_bib22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1073\/pnas.63.1.23","article-title":"Dependence of the kinetics of singlet-singlet energy transfer on spectral overlap","volume":"63","author":"Haugland","year":"1969","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.121.000688_bib23","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.121.000688_bib24","doi-asserted-by":"crossref","first-page":"31257","DOI":"10.1074\/jbc.M502577200","article-title":"Mechanism of the maturation process of SARS-CoV 3CL protease","volume":"280","author":"Hsu","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.121.000688_bib25","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2165\/00003495-200060060-00009","article-title":"Lopinavir","volume":"60","author":"Hurst","year":"2000","journal-title":"Drugs"},{"key":"10.1124\/jpet.121.000688_bib26","doi-asserted-by":"crossref","first-page":"624163","DOI":"10.3389\/fchem.2020.624163","article-title":"In silico exploration of inhibitors for SARS-CoV-2's papain-like protease","volume":"8","author":"Huynh","year":"2021","journal-title":"Front Chem"},{"key":"10.1124\/jpet.121.000688_bib27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/jpet.121.000688_bib28","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1021\/acs.jproteome.0c00836","article-title":"Structure-based screening to discover new inhibitors for papain-like proteinase of SARS-CoV-2: an in silico study","volume":"20","author":"Jamalan","year":"2021","journal-title":"J Proteome Res"},{"key":"10.1124\/jpet.121.000688_bib29","doi-asserted-by":"crossref","first-page":"2021579118","DOI":"10.1073\/pnas.2021579118","article-title":"Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection","volume":"118","author":"Jan","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.121.000688_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1124\/jpet.121.000688_bib31","doi-asserted-by":"crossref","first-page":"e106275","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J"},{"key":"10.1124\/jpet.121.000688_bib32","doi-asserted-by":"crossref","first-page":"e02577-20","DOI":"10.1128\/AAC.02577-20","article-title":"Kinetic characterization and inhibitor screening for the proteases leading to identification of drugs against SARS-CoV-2","volume":"65","author":"Kuo","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/jpet.121.000688_bib33","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.bbrc.2004.04.098","article-title":"Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate","volume":"318","author":"Kuo","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.121.000688_bib34","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1038\/s41467-020-19662-4","article-title":"Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"key":"10.1124\/jpet.121.000688_bib35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2017.11.001","article-title":"Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein","volume":"149","author":"Lei","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1124\/jpet.121.000688_bib36","series-title":"Hepatitis C viruses: genomes and molecular biology","article-title":"HCV NS3-4A Serine Protease","author":"Lin","year":"2006"},{"key":"10.1124\/jpet.121.000688_bib37","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1021\/acscentsci.0c01186","article-title":"Simeprevir potently suppresses sars-cov-2 replication and synergizes with remdesivir","volume":"7","author":"Lo","year":"2021","journal-title":"ACS Cent Sci"},{"key":"10.1124\/jpet.121.000688_bib38","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/nrc2228","article-title":"Emerging roles of proteases in tumour suppression","volume":"7","author":"L\u00f3pez-Ot\u00edn","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/jpet.121.000688_bib39","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1021\/acs.jproteome.0c00430","article-title":"Targeting proteases for treating COVID-19","volume":"19","author":"Luan","year":"2020","journal-title":"J Proteome Res"},{"key":"10.1124\/jpet.121.000688_bib40","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1021\/acsptsci.0c00093","article-title":"Can papain-like protease inhibitors halt SARS-CoV-2 replication?","volume":"3","author":"Maiti","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1124\/jpet.121.000688_bib41","series-title":"Fluorescent energy transfer nucleic acid probes: designs and protocols","first-page":"3","article-title":"Selection of Fluorophore and Quencher Pairs for Fluorescent Nucleic Acid Hybridization Probes","author":"Marras","year":"2006"},{"key":"10.1124\/jpet.121.000688_bib42","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/acsnano.0c07383","article-title":"Uncovering flexible active site conformations of SARS-CoV-2 3CL proteases through protease pharmacophore clusters and COVID-19 drug repurposing","volume":"15","author":"Pathak","year":"2021","journal-title":"ACS Nano"},{"key":"10.1124\/jpet.121.000688_bib43","doi-asserted-by":"crossref","first-page":"623971","DOI":"10.3389\/fchem.2020.623971","article-title":"Identification of small molecule inhibitors of the deubiquitinating activity of the SARS-CoV-2 papain-like protease: in silico molecular docking studies and in vitro enzymatic activity assay","volume":"8","author":"Pitsillou","year":"2020","journal-title":"Front Chem"},{"key":"10.1124\/jpet.121.000688_bib44","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","article-title":"SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model","volume":"371","author":"Qiao","year":"2021","journal-title":"Science"},{"key":"10.1124\/jpet.121.000688_bib45","doi-asserted-by":"crossref","first-page":"eabc5332","DOI":"10.1126\/scitranslmed.abc5332","article-title":"3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice","volume":"12","author":"Rathnayake","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1124\/jpet.121.000688_bib46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/v13020173","article-title":"Development of a cell-based luciferase complementation assay for identification of SARS-CoV-2 3CLpro inhibitors","volume":"13","author":"Rawson","year":"2021","journal-title":"Viruses"},{"key":"10.1124\/jpet.121.000688_bib47","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41589-020-00689-z","article-title":"SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging","volume":"17","author":"Rut","year":"2021","journal-title":"Nat Chem Biol"},{"key":"10.1124\/jpet.121.000688_bib48","doi-asserted-by":"crossref","first-page":"eabd4596","DOI":"10.1126\/sciadv.abd4596","article-title":"Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design","volume":"6","author":"Rut","year":"2020","journal-title":"Sci Adv"},{"key":"10.1124\/jpet.121.000688_bib49","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.121.000688_bib50","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"10.1124\/jpet.121.000688_bib51","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/2472555220963667","article-title":"High-throughput screening for drugs that inhibit papain-like protease in SARS-CoV-2","volume":"25","author":"Smith","year":"2020","journal-title":"SLAS Discov"},{"key":"10.1124\/jpet.121.000688_bib52","article-title":"Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19","author":"Steuten","year":"2021","journal-title":"ACS Cent Sci"},{"key":"10.1124\/jpet.121.000688_bib53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.antiviral.2009.10.003","article-title":"Fifteen years of HIV protease inhibitors: raising the barrier to resistance","volume":"85","author":"Wensing","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1124\/jpet.121.000688_bib54","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1371\/journal.pbio.0030324","article-title":"Design of wide-spectrum inhibitors targeting coronavirus main proteases","volume":"3","author":"Yang","year":"2005","journal-title":"PLoS Biol"},{"key":"10.1124\/jpet.121.000688_bib55","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.121.000688_bib56","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/jmv.25729","article-title":"A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option","volume":"92","author":"Yao","year":"2020","journal-title":"J Med Virol"},{"key":"10.1124\/jpet.121.000688_bib57","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1124\/jpet.121.000688_bib58","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1021\/jacs.8b13042","article-title":"Designing a green fluorogenic protease reporter by flipping a beta strand of GFP for imaging apoptosis in animals","volume":"141","author":"Zhang","year":"2019","journal-title":"J Am Chem Soc"},{"key":"10.1124\/jpet.121.000688_bib59","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1021\/acsptsci.0c00108","article-title":"Identification of SARS-CoV-2 3CL protease inhibitors by a quantitative high-throughput screening","volume":"3","author":"Zhu","year":"2020","journal-title":"ACS Pharmacol Transl Sci"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.121.000688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T16:53:00Z","timestamp":1740675180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524257025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0022356524257025"],"URL":"https:\/\/doi.org\/10.1124\/jpet.121.000688","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.121.000688","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"U.S. Government work not protected by U.S. copyright","name":"copyright","label":"Copyright"}]}}